Intetumumab
Monoclonal antibody
NY (what is this?) (verify) Intetumumab is a human monoclonal antibody targeting integrins[1] that was being studied for the treatment of solid tumors.[2]
Intetumumab was developed by Centocor, Inc.
Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[3]
References
- ^ Łasiñska I, Mackiewicz J (2019). "Integrins as A New Target for Cancer Treatment". Anti-Cancer Agents in Medicinal Chemistry. 19 (5): 580–586. doi:10.2174/1871520618666181119103413. PMID 30451118. S2CID 53952455.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association.
- ^ "Intetumumab". AdisInsight. Retrieved 30 January 2017.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e